Abstract: Objective To investigate the status of BRAFV600E mutation in stage ⅠⅡ papillary thyroid cancer（PTC） and evaluate the correlation between BRAFV600E mutation and clinicopathological characteristics and prognosis.
MethodsThe BRAFV600E mutation of stage Ⅰ-Ⅱ PTC was detected by RTPCR. The relationship was analyzed between BRAFV600E mutation and clinicopathological characteristics and prognosis of PTC. Results The BRAFV600E mutation rate in 374 cases of PTC was 40.37％（151／374）. The BRAFV600E mutation correlated with capsule invasion， multifocality， multiple radioiodine courses（P＜0.05）. Thirtyone patients were recurrent in 374 cases of PTC, including 22 patients with BRAFV600E mutation. The median survival time was 5.3 years（95%CI： 3.9-6.7） in the recurrent PTC patients with BRAFV600E mutation which had shorter trend compared with 7.0 years（95%CI： 5.1-8.9） in the patients without mutation. But no statistical difference was found. The BRAFV600E mutation and capsule invasion were prognostic factors in predicting the recurrence of the disease by multiple logistic regression test（P＜0.05）. Conclusion The BRAFV600E mutation may be an independent prognostic factor in predicting the prognosis of stage Ⅰ-Ⅱ PTC patients.